<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>22341751</identifier>
<setSpec>1578-1852</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Fortún, Jesús</dc:author>
<dc:author>Moreno, Santiago</dc:author>
<dc:author>Fresco, Gema</dc:author>
<dc:author>Meije, Yolanda</dc:author>
<dc:description xml:lang="en">Invasive aspergillosis, chronic pulmonary aspergillosis and allergic bronchopulmonary aspergillosis are the clinical forms of aspergillosis. Although there is a great number of Aspergillus species, Aspergillus fumigatus-complex is the more frequent aetiological agent, regardless of clinical form or baseline condition. The increase in immunosuppressive agents and the higher use of corticosteroids in chronic obstructive pulmonary disease have led to aspergillosis becoming more prominent in recent years. Galactomannan detection and radiological diagnostic images complement the limitations of microbiology cultures in these patients. Voriconazole and liposomal amphotericin B are the gold standard in patients requiring therapy, and posaconazole, itraconazole, caspofungin and other echinocandins are effective alternatives. The prognosis depends of clinical forms and characteristics of the host, but it is particularly poor in the disseminated invasive forms.</dc:description>
<dc:type>Journal Article</dc:type>
<dc:language>es</dc:language>
<dc:date>2012 Apr </dc:date>
<dc:title xml:lang="es">Aspergilosis. Formas clínicas y tratamiento.</dc:title>
<dc:title xml:lang="en">[Aspergillosis. Clinical forms and treatment].</dc:title>
<dc:publisher>Enfermedades infecciosas y microbiologia clinica</dc:publisher>
</metadata>
</record>
</pubmed-document>
